ATE437641T1 - Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis - Google Patents
Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosisInfo
- Publication number
- ATE437641T1 ATE437641T1 AT04752432T AT04752432T ATE437641T1 AT E437641 T1 ATE437641 T1 AT E437641T1 AT 04752432 T AT04752432 T AT 04752432T AT 04752432 T AT04752432 T AT 04752432T AT E437641 T1 ATE437641 T1 AT E437641T1
- Authority
- AT
- Austria
- Prior art keywords
- amyloid
- microgliosis
- reducing
- animals
- neurotoxicity
- Prior art date
Links
- 206010029350 Neurotoxicity Diseases 0.000 title abstract 3
- 206010044221 Toxic encephalopathy Diseases 0.000 title abstract 3
- 230000007388 microgliosis Effects 0.000 title abstract 3
- 230000007135 neurotoxicity Effects 0.000 title abstract 3
- 231100000228 neurotoxicity Toxicity 0.000 title abstract 3
- 230000003941 amyloidogenesis Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 3
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 abstract 3
- 230000003942 amyloidogenic effect Effects 0.000 abstract 3
- 230000002490 cerebral effect Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229960005366 nilvadipine Drugs 0.000 abstract 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 2
- 230000006933 amyloid-beta aggregation Effects 0.000 abstract 2
- 230000001537 neural effect Effects 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 230000009529 traumatic brain injury Effects 0.000 abstract 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47069403P | 2003-05-15 | 2003-05-15 | |
| PCT/US2004/015417 WO2004110354A2 (en) | 2003-05-15 | 2004-05-17 | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437641T1 true ATE437641T1 (de) | 2009-08-15 |
Family
ID=33551420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04752432T ATE437641T1 (de) | 2003-05-15 | 2004-05-17 | Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7732467B2 (de) |
| EP (1) | EP1628663B1 (de) |
| JP (1) | JP4971794B2 (de) |
| CN (1) | CN100444840C (de) |
| AT (1) | ATE437641T1 (de) |
| CA (1) | CA2525970C (de) |
| DE (1) | DE602004022284D1 (de) |
| DK (1) | DK1628663T3 (de) |
| ES (1) | ES2334029T3 (de) |
| WO (1) | WO2004110354A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006203819A1 (en) * | 2005-01-07 | 2006-07-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds |
| ATE526965T1 (de) * | 2005-04-15 | 2011-10-15 | Res & Innovation S P A | Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung |
| CN101400349A (zh) * | 2006-03-01 | 2009-04-01 | 罗斯坎普研究有限责任公司 | 抑制β-淀粉样蛋白产生的化合物 |
| WO2008070875A2 (en) * | 2006-12-08 | 2008-06-12 | Roskamp Research Llc | Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production |
| US8709394B2 (en) * | 2007-09-28 | 2014-04-29 | Ndsu Research Foundation | Antimicrobial polysiloxane materials containing metal species |
| ES2449594T3 (es) * | 2007-10-05 | 2014-03-20 | Alzheimer's Institute Of America, Inc. | Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina |
| WO2009046338A1 (en) * | 2007-10-05 | 2009-04-09 | Roskamp Research Llc | Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer |
| US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
| JP2012526844A (ja) * | 2009-05-15 | 2012-11-01 | ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | Ｍｃｉおよびアルツハイマー病の処置 |
| EP2311823A1 (de) * | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridinverbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloidproteinen oder zur Behandlung von Augenkrankheiten |
| KR20140128230A (ko) | 2013-04-26 | 2014-11-05 | 한국과학기술연구원 | 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338322A (en) | 1975-07-02 | 1982-07-06 | Fujisawa Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same |
| JPS6038322A (ja) | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固形製剤 |
| JPS61129140A (ja) | 1984-11-27 | 1986-06-17 | Nitto Electric Ind Co Ltd | 医薬組成物 |
| GB8431119D0 (en) | 1984-12-10 | 1985-01-16 | Fujisawa Pharmaceutical Co | Anti-arteriosclerotic composition |
| US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| EP0294601B1 (de) | 1987-06-12 | 1993-01-20 | American Cyanamid Company | Transkutane Verabreichung von Pharmazeutika |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US5045553A (en) | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
| US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
| US5160734A (en) | 1987-11-25 | 1992-11-03 | American Cyanamid Company | Sustained release delivery system for substituted dihydropyridine calcium channel blockers |
| ES2037179T3 (es) | 1987-11-25 | 1993-06-16 | American Cyanamid Company | Sistema de liberacion sostenida (controlada) para bloqueadores de canales de calcio de dihidropiridina. |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP3479532B2 (ja) | 1989-03-31 | 2003-12-15 | ザ・チルドレンズ・メディカル・センター・コーポレーション | エイズの痴呆症、脊髄障害および失明の治療 |
| JP2867462B2 (ja) | 1989-09-12 | 1999-03-08 | 藤沢薬品工業株式会社 | 経皮吸収用製剤 |
| JPH03117658A (ja) | 1989-09-29 | 1991-05-20 | Mazda Motor Corp | 外燃式ロータリピストンエンジン |
| JP2920956B2 (ja) | 1989-10-06 | 1999-07-19 | 藤沢薬品工業株式会社 | ニルバジピン含有持続性錠剤 |
| JPH06500554A (ja) | 1990-08-23 | 1994-01-20 | ザ・チルドレンズ・メディカル・センター・コーポレイション | エイズ性痴呆、脊髄障害、末梢神経障害、および視覚喪失の治療 |
| WO1993005770A1 (fr) | 1991-09-20 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Preparation a longue duree d'action |
| JPH05139974A (ja) | 1991-11-26 | 1993-06-08 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固体分散体の製造法 |
| DE4141646A1 (de) | 1991-12-17 | 1993-06-24 | Klinge Co Chem Pharm Fab | Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| DE4229805A1 (de) * | 1992-09-07 | 1994-03-24 | Werner E G Prof Dr Mueller | Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden |
| US5721263A (en) | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| WO1997040834A1 (en) | 1996-04-26 | 1997-11-06 | Fujisawa Pharmaceutical Co., Ltd. | Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines |
| US6271259B1 (en) * | 1996-05-07 | 2001-08-07 | Ito En, Ltd. | Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death |
| KR100222306B1 (ko) | 1996-11-20 | 1999-10-01 | 이병언 | 닐바디핀 속효성 고형제제 및 이의 제조방법 |
| WO1999063992A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Novel calcium channel drugs and uses |
| CA2319142A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Novel therapeutic agents for membrane transporters |
| TR200100062T2 (tr) | 1998-07-10 | 2001-06-21 | Novartis Ag | Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu |
| EP1260232A1 (de) | 2000-03-03 | 2002-11-27 | Fujisawa Pharmaceutical Co., Ltd. | Heilmittel für die behandlung von bösartigen-tumorassoziierten neurosen und azoor-viralen oder analogen erkrankungen |
| DE60128683T2 (de) | 2000-04-11 | 2008-01-24 | Sankyo Co., Ltd. | Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten |
| US20020042405A1 (en) | 2000-07-27 | 2002-04-11 | Schuh Joseph R. | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| JP2001335483A (ja) | 2000-05-30 | 2001-12-04 | Nichiko Pharmaceutical Co Ltd | ニルバジピン含有製剤 |
| JP3968687B2 (ja) | 2000-09-13 | 2007-08-29 | 東和薬品株式会社 | 易吸収性ニルバジピン錠 |
| JP3470096B2 (ja) | 2000-09-19 | 2003-11-25 | 沢井製薬株式会社 | ニルバジピン含有易溶性固形製剤およびその製造法 |
| BR0116255A (pt) | 2000-12-19 | 2003-12-30 | Merck Patent Gmbh | Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1) |
| WO2002049651A1 (de) | 2000-12-19 | 2002-06-27 | Merck Patent Gmbh | Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
| US7083642B2 (en) | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
| CA2333494A1 (en) | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
| WO2002096415A2 (en) | 2001-05-25 | 2002-12-05 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
| PE20040468A1 (es) | 2002-05-17 | 2004-09-14 | Novartis Ag | Combinacion de compuestos organicos |
| PT1507558E (pt) | 2002-05-17 | 2011-11-23 | Novartis Ag | Composição farmacêutica compreendendo um inibidor de renina, um bloqueador do canal de cálcio e um diurético |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| JP2003146878A (ja) | 2002-11-22 | 2003-05-21 | Sawai Pharmaceutical Co Ltd | ニルバジピン含有易溶性固形製剤およびその製造法 |
| NZ541282A (en) * | 2002-12-24 | 2009-02-28 | Bellus Health International Ltd | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| JP2004002460A (ja) | 2003-07-29 | 2004-01-08 | Towa Yakuhin Kk | 易吸収性ニルバジピン錠の製造法 |
-
2004
- 2004-05-17 WO PCT/US2004/015417 patent/WO2004110354A2/en not_active Ceased
- 2004-05-17 ES ES04752432T patent/ES2334029T3/es not_active Expired - Lifetime
- 2004-05-17 DE DE602004022284T patent/DE602004022284D1/de not_active Expired - Lifetime
- 2004-05-17 CA CA2525970A patent/CA2525970C/en not_active Expired - Fee Related
- 2004-05-17 JP JP2006533144A patent/JP4971794B2/ja not_active Expired - Lifetime
- 2004-05-17 CN CNB2004800171974A patent/CN100444840C/zh not_active Expired - Fee Related
- 2004-05-17 DK DK04752432.7T patent/DK1628663T3/da active
- 2004-05-17 AT AT04752432T patent/ATE437641T1/de not_active IP Right Cessation
- 2004-05-17 US US10/847,630 patent/US7732467B2/en active Active
- 2004-05-17 EP EP04752432A patent/EP1628663B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004110354A2 (en) | 2004-12-23 |
| CN1809352A (zh) | 2006-07-26 |
| EP1628663A4 (de) | 2006-05-24 |
| US7732467B2 (en) | 2010-06-08 |
| EP1628663B1 (de) | 2009-07-29 |
| DE602004022284D1 (de) | 2009-09-10 |
| CA2525970A1 (en) | 2004-12-23 |
| EP1628663A2 (de) | 2006-03-01 |
| WO2004110354A3 (en) | 2005-02-10 |
| JP4971794B2 (ja) | 2012-07-11 |
| CA2525970C (en) | 2011-03-22 |
| CN100444840C (zh) | 2008-12-24 |
| DK1628663T3 (da) | 2010-03-08 |
| HK1092358A1 (en) | 2007-02-09 |
| JP2007501277A (ja) | 2007-01-25 |
| ES2334029T3 (es) | 2010-03-04 |
| US20050009885A1 (en) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| ATE552837T1 (de) | Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen | |
| DE69533040D1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
| PH12021553223A1 (en) | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | |
| EP1432310A4 (de) | Verfahren zur behandlung von chronischem herzversagen und/oder erhöhtem cholesterinspiegel mittels 3,5-diiodthyropropionsäure, sowie verfahren zu ihrer herstellung | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| UY28817A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegerativos | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| ATE412415T1 (de) | Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| DE69938653D1 (de) | Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| WO2006001877A3 (en) | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen | |
| ATE437641T1 (de) | Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| PH12021553232A1 (en) | 2h-indazole derivatives and their use in the treatment of disease | |
| DE60312505D1 (de) | Injektion aus ixeris sonchifolia zur behandlung von kardiozerebralen gefässerkrankungen und funduserkrankungen sowie herstellungsverfahren dafür | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| WO2005046605A3 (en) | Compositions and methods of treating neurological diseases | |
| ATE285773T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| IL176453A0 (en) | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases | |
| ATE448779T1 (de) | Methode zur behandlung trockener augen und uveitis | |
| Estrada et al. | Transcranial magnetic stimulation on rodent models | |
| DE60131100D1 (de) | Verfahren zur behandlung bestimmter augenkrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |